Is FRX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

954 people get FRX articles and Market Currents by email alert.

Get email alerts on FRX »

HEADLINES:

Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
PropThink • Tue, May 21 • 4 Comments
Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference

Business Wire (Fri, 8:08AM)
Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting

Business Wire (Thu, 8:00AM)
Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure

Business Wire (May 9, 2013)
Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD

Business Wire (May 1, 2013)
Synergy On Sale: Why This Opportunity Shouldn't Be Missed
PropThink • Thu, Apr 25 • 6 Comments
Forest Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcript
Tue, Apr 23
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization

Business Wire (Apr 23, 2013)
Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis
Jason Napodano • Wed, Apr 17 • 16 Comments
Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD

Business Wire (Apr 16, 2013)
GlaxoSmithKline: Not Making The Right Moves
StockRiters • Sun, Apr 14 • 9 Comments
Cramer's Mad Money - 16 Things To Watch In The Week Ahead (3/12/13)
SA Editor Miriam Metzinger • Sun, Apr 14 • 3 Comments
Is Acadia A Buy After Jumping Over 50%?
C.R. Jackson • Fri, Apr 12 • 9 Comments
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Fourth Quarter Earnings

Business Wire (Apr 2, 2013)
Forest Laboratories' Management Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13
Forest Laboratories' Management Presents at Citi 2013 Global Healthcare Conference (Transcript)
Wed, Feb 27
Carl Icahn's Latest Top 5: How Should Investors Play It?
Insider Monkey • Thu, Feb 21 • 1 Comment
Lundbeck Could Cheer Up Patient Investors
Stephen Simpson • Wed, Feb 13
High-Quality Glaxo Could Still Have Something Left
Stephen Simpson • Fri, Feb 8 • 10 Comments
Post-Tysabri, Will Elan Waste The Windfall?
Stephen Simpson • Fri, Feb 8 • 5 Comments

To learn more about Seeking Alpha Pro, click here.

Forest Laboratories Goes Off Lexapro - What Happens Next?
Pharma Reports • Tue, Feb 5 • 6 Comments
Why Is Carl Icahn Buying Large Blocks Of Forest Laboratories?
Brian L. Wilson • Thu, Sep 6, 2012 • 3 Comments
Plenty Of Analysts Scared To Go Into Forest Labs
Stephen Simpson • Tue, Jul 17, 2012 • 2 Comments
Earnings Preview: Forest Laboratories
Vytautas Drumelis • Tue, Jul 10, 2012
Investors Can Still Benefit From Street's Doubts About Forest Labs
Stephen Simpson • Tue, Apr 17, 2012
Likely Approval Spurring Rise Of Forest Laboratories Shares
Brian L. Wilson • Mon, Apr 9, 2012 • 2 Comments
Forest Labs May Soon Lose Its Independence: Options Play
Nino Armienti • Tue, Mar 13, 2012 • 10 Comments
Forest Laboratories: Uncertainty Over Future Winners Increases Risk
Frank Voisin • Wed, Dec 7, 2011 • 1 Comment
Forest Laboratories Misses Despite Increased Revenues
Zacks Investment Research • Wed, Oct 19, 2011
Forest Labs Earnings Preview
Zacks Investment Research • Fri, Oct 14, 2011
Forest Labs Is Not The Value Stock It Appears To Be
Vince Martin • Thu, Sep 1, 2011
Feds Will Not Ban Forest CEO From Health Programs
Pharmalot • Mon, Aug 8, 2011
Forest Labs: A Growing Pipeline but Long-Term Growth Remains a Concern
Zacks Investment Research • Wed, Jul 20, 2011
Forest Labs Earnings Preview
Zacks Investment Research • Wed, Jul 13, 2011
Forest Labs: 3 Reasons to Finally Be Bullish
Follow My Alpha • Mon, Jul 11, 2011 • 2 Comments
Forest Labs: Earnings Preview
Zacks Investment Research • Thu, Apr 14, 2011 • 2 Comments
Clinical Data and Forest Labs Agree to Split the Risk
Stephen Simpson • Tue, Feb 22, 2011 • 14 Comments
Earnings Scorecard: Forest Labs
Zacks Investment Research • Mon, Jan 31, 2011
Forest Labs Impresses Again: Beats Q3 Estimates on Strong Namenda Sales
Zacks Investment Research • Tue, Jan 18, 2011
Forest Labs: Earnings Preview
Zacks Investment Research • Fri, Jan 14, 2011 • 1 Comment

Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
PropThink • Tue, May 21 • 4 Comments
Synergy On Sale: Why This Opportunity Shouldn't Be Missed
PropThink • Thu, Apr 25 • 6 Comments
Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis
Jason Napodano • Wed, Apr 17 • 16 Comments
GlaxoSmithKline: Not Making The Right Moves
StockRiters • Sun, Apr 14 • 9 Comments
Cramer's Mad Money - 16 Things To Watch In The Week Ahead (3/12/13)
SA Editor Miriam Metzinger • Sun, Apr 14 • 3 Comments
Is Acadia A Buy After Jumping Over 50%?
C.R. Jackson • Fri, Apr 12 • 9 Comments
Carl Icahn's Latest Top 5: How Should Investors Play It?
Insider Monkey • Thu, Feb 21 • 1 Comment
Lundbeck Could Cheer Up Patient Investors
Stephen Simpson • Wed, Feb 13
High-Quality Glaxo Could Still Have Something Left
Stephen Simpson • Fri, Feb 8 • 10 Comments
Post-Tysabri, Will Elan Waste The Windfall?
Stephen Simpson • Fri, Feb 8 • 5 Comments
Positive Top Line Data For Synergy: A Ripe Time For Acquisition
Logical Assessment • Wed, Jan 30 • 8 Comments
Stock Watch Tuesday, 15 January
VFC's Stock House • Tue, Jan 15 • 11 Comments
4 Healthcare Stocks Trading Near Highs Being Sold Off By Hedge Funds
Kapitall • Thu, Jan 10
3 Undervalued Healthcare Stocks Being Sold By Hedge Funds
Kapitall • Thu, Nov 29, 2012 • 1 Comment
For NovaBay, Simplicity Is The Father Of Invention
Ryan's View • Mon, Nov 12, 2012
Only 2 High-Growth Healthcare Stocks Are Being Bought Up By Insiders
Kapitall • Fri, Nov 2, 2012
Cramer's Lightning Round - Windstream Is Tough (10/25/12)
SA Editor Miriam Metzinger • Fri, Oct 26, 2012 • 4 Comments
Tonix: A Small Biotech With The Potentially Huge Key To The Fibromyalgia Puzzle
Jason Napodano • Thu, Oct 25, 2012 • 19 Comments
Ironwood Implies Upside For Synergy; Lessons Learned From Dendreon
Logical Assessment • Thu, Oct 25, 2012 • 10 Comments
Avanir Pharmaceuticals: Pipeline Overview And Stock Valuation
LifeSci Advisors • Wed, Oct 24, 2012 • 3 Comments

Forest Laboratories Management Discusses Q4 2013 Results - Earnings Call Transcript
Tue, Apr 23
Forest Laboratories' Management Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13
Forest Laboratories' Management Presents at Citi 2013 Global Healthcare Conference (Transcript)
Wed, Feb 27
Forest Laboratories Management Discusses Q3 2013 Results - Earnings Call Transcript
Tue, Jan 15
Forest Laboratories Management Discusses Q2 2013 Results - Earnings Call Transcript
Tue, Oct 16, 2012
Forest Laboratories Management Discusses Q1 2013 Results - Earnings Call Transcript
Tue, Jul 17, 2012
Forest Laboratories' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Wed, Apr 18, 2012
Forest Laboratories Management Discusses Q3 2012 Results - Earnings Call Transcript
Tue, Jan 17, 2012
Forest Laboratories Management Discusses Q2 2012 Results - Earnings Call Transcript
Tue, Oct 18, 2011
Forest Laboratories Management Discusses Q1 2012 Results - Earnings Call Transcript
Tue, Jul 19, 2011
Forest Laboratories Management Discusses Q4 2011 Results - Earnings Call Transcript
Tue, Apr 19, 2011
Forest Laboratories Management Discusses Q3 2011 Results - Earnings Call Transcript
Tue, Jan 18, 2011
Forest Laboratories Inc. Management Discusses F2Q2011 Results - Earnings Call Transcript
Tue, Oct 19, 2010
Forest Laboratories F1Q11 (Qtr End 6/30/10) Earnings Call Transcript
Tue, Jul 20, 2010
Forest Laboratories, Inc. F4Q10 (Qtr End 3/31/10) Earnings Call Transcript
Tue, Apr 20, 2010
Forest Laboratories, Inc. F3Q10 (Qtr End 12/31/09) Earnings Call Transcript
Tue, Jan 19, 2010
Forest Laboratories Inc. F2Q10 (Qtr End 30/09/09) Earnings Call Transcript
Tue, Oct 20, 2009
Forest Laboratories Inc. F1Q10 (Qtr End 06/30/09) Earnings Call Transcript
Tue, Jul 21, 2009
Forest Laboratories, Inc Q1 2009 Earnings Call Transcript
Tue, Apr 21, 2009
Forest Laboratories Inc., F3Q09 (Qtr End 12/31/08) Earnings Call Transcript
Tue, Jan 20, 2009

Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference

Business Wire (Fri, 8:08AM)
Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting

Business Wire (Thu, 8:00AM)
Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure

Business Wire (May 9, 2013)
Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD

Business Wire (May 1, 2013)
Early Movers: DD, TRV, UTX & More

at CNBC.com (Apr 23, 2013)
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization

Business Wire (Apr 23, 2013)
A Make-or-Break Week Ahead for the Stock Market

at CNBC.com (Apr 20, 2013)
Early Movers: KO, GS, JNJ & More

at CNBC.com (Apr 16, 2013)
Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD

Business Wire (Apr 16, 2013)
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Fourth Quarter Earnings

Business Wire (Apr 2, 2013)
Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension

Business Wire (Jan 17, 2013)
Forest Labs Swings to 3Q Loss as Lexapro Patent Expires

at Fox Business (Jan 15, 2013)
Indications: Stock futures decline amid earnings jitters

at MarketWatch.com (Jan 15, 2013)
Stocks to Watch: Big earnings on Tuesday: Forest Labs, Lennar

at MarketWatch.com (Jan 15, 2013)
Early Movers: LEN, FRX, LULU & More

at CNBC.com (Jan 15, 2013)
Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings

Business Wire (Jan 15, 2013)
Slide Show: Spoiler alert: 9 stocks that may shock on earnings

at MarketWatch.com (Jan 8, 2013)
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation

Business Wire (Jan 3, 2013)
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Third Quarter Earnings

Business Wire (Jan 2, 2013)
Forest Laboratories and Almirall announce commercial availability of Tudorza™ Pressair™ in US pharmacies

Business Wire (Dec 11, 2012)

FRX vs. ETF Alternatives

Company Description

BUSINESS: General

Forest Laboratories, Inc. and its subsidiaries develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription. Our most important United States products consist of branded ethical drug specialties marketed... More

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 4:31 PM Forest Laboratories (FRX) and Almirall announce positive topline results from a second six-month Phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate, delivered in the Pressair inhaler. Results showed the combination demonstrated statistically significant improvements in change from baseline for the co-primary endpoints. Comment! [Healthcare, Global & FX]
Tuesday, April 23, 8:30 AM Ironwood Pharmaceuticals (IRWD) sinks 13.3% premarket after saying sales of Linzess — the IBS drug the company markets with Forest Labs (FRX) — were $4.5M for Q1 versus expectations of $11-13M. Credit Suisse and Wedbush previously said early evidence suggested demand for the drug was strong. Irina Rivkind at Cantor says Synergy's (SGYP) investigational candidate plecanatide has the potential to achieve revenue parity with Linzess. Comment! [On the Move, Healthcare]
Tuesday, April 23, 7:05 AM Forest Labs (FRX): FQ4 EPS of $0.25 beats by $0.09. Revenue of $783.2M (-21.4% Y/Y) misses by $23.8M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 23, 12:05 AM Notable earnings before Tuesday’s open: ACI, AKS, AOS, APD, ARMH, CIT, CNC, COH, DAL, DD, DFS, EAT, ECA, FMER, FRX, GCI, GNTX, IDXX, IIVI, IR, IRWD, ITW, JCI, JNS, LCC, LECO, LMT, LXK, MOLX, PCAR, PCH, PII, PMT, PNR, R, RAI, RF, RSH, SNV, ST, TRV, UTX, WAT, XRX 1 Comment [Earnings]
Monday, April 22, 5:30 PM Notable earnings before Tuesday’s open: ACI, AKS, AOS, APD, ARMH, CIT, CNC, COH, DAL, DD, DFS, EAT, ECA, FMER, FRX, GCI, GNTX, IDXX, IIVI, IR, IRWD, ITW, JCI, JNS, LCC, LECO, LMT, LXK, MOLX, PCAR, PCH, PII, PMT, PNR, R, RAI, RF, RSH, SNV, ST, TRV, UTX, WAT, XRX Comment! [Earnings]
Tuesday, April 16, 7:17 AM Carl Ichan-backed Forest Laboratories (FRX) and Almirall say a combination COPD treatment of aclidinium and formoterol met both endpoints in a Phase III clinical trial. Data from a second Phase III trial is forthcoming and, if positive, the companies expect to file an NDA with the FDA. Comment! [Healthcare]
Tuesday, April 9, 11:44 AM Synergy Pharmaceuticals (SGYP +10.3%) soars on heavy volume after Cantor Fitzgerald raises its price target on the shares to $15 from $12. Irina Rivkind says the company's lead investigational drug plecanatide can "achieve revenue parity" with Ironwood (IRWD -0.5%) and Forest Laboratories' (FRX -0.2%) Linzess, an FDA approved treatment for constipation. Comment! [Healthcare, On the Move]
Tuesday, February 12, 3:33 PM AstraZeneca Plc (AZN) needs to make a big buy to reverse its slide, recommends a number of Wall Street analysts, saying the drugmaker needs a "transformational deal" to return it to profit growth. A deal for Shire (SHPG +0.2%) or Forest Labs (FRX +0.7%) would rival its's $15B acquisition of MedImmune in 2007. SHPG could help fill the gap with patent-protected medicines for rare diseases and leading ADD therapies, says Kepler Capital Markets, while FRX's lung treatment would bolster the company's respiratory business. Comment! [Healthcare, M&A]
Tuesday, January 15, 12:47 PM Ironwood Pharmaceuticals (IRWD +1%) gives a Q4 business update on the commercial launch of its irritable bowel syndrome Linzess in the U.S., saying its partner, Forest Laboratories (FRX) reported Q4 product sales of $19.2M. The company also said another commercial partner, Almirall, received approval for Constella for the treatment of moderate to severe irritable bowel syndrome in the European Union. Commercial launch will be initiated in the first half of FY13. Comment! [Healthcare, On the Move]
Tuesday, January 15, 8:13 AM More on Forest Laboratories (FRX -5%) FQ3: swings to net loss of $153.6M from profit of $278.4M, with earnings hurt by the expiration of Lexapro's patent in March 2012 and upfront licensing payments of $76M. Expects FY 2013 EPS at lower end of forecast of $0.45-$0.60 vs consensus of $0.25 - which looks to be a substantial discrepancy - and revenue of $3.1-$3.2B vs $3.15B. (PR) Comment! [Earnings, Healthcare, On the Move]
Tuesday, January 15, 7:03 AM Forest Laboratories (FRX): FQ3 EPS of -$0.21 misses by $0.07. Revenue of $722.7M (-40.2% Y/Y) misses by $38M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, January 15, 12:05 AM Notable earnings before Tuesday’s open: FRX, LEN Comment! [Earnings]
Monday, January 14, 5:30 PM Notable earnings before Tuesday’s open: FRX, LEN Comment! [Earnings]
Friday, December 7, 2012, 2:28 PM Forest Laboratories (FRX -0.2%) negotiates a new credit agreement with JPMorgan Chase Bank, entering into a five-year unsecured $750M revolving credit facility which expires in December 2017. The new agreement replaces the company’s prior $500M revolving credit facility which was scheduled to expire today. Comment! [Healthcare]
Tuesday, October 16, 2012, 8:28 AM More on Forest Laboratories (FRX -3%) FQ2: net profit plunges to $20.8M from $249.8M last year, with the the patent expiration for Lexapro continuing to hurt. Forecasts FY adjusted EPS of $0.45-$0.60 vs. consensus of $0.67. Sales breakdown: Namenda +9.1% to $367.6M, Bystolic +29.4% to $106.5M, "next-generation" products +69% to $202M. (PR) Comment! [Earnings, Healthcare, On the Move]
Tuesday, October 16, 2012, 8:11 AM Forest Laboratories (FRX): FQ2 EPS of $0.15 misses by $0.05. Revenue of $760.6M (-35% Y/Y) misses by $14M. Shares -1.1% premarket. (PR) Comment! [Earnings, Healthcare, On the Move]

VFC's Stock House
Stock Watch Wednesday: $BA, $FB, $GOOG, $WFC, $GS, $JPM, $IRWD, $FRX, $ONVO.PK, $DDD, $SYSS, $AAPL - http://bit.ly/cAHZ42
Jan 16, 7:09 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch- $AMRN, $SGYP, $IRWD, $FRX, $SI, $TEV, $AZN, $IMSC.PK, $SIRI, $CTSO.OB, $GE, $JWM, $GMCR, $SBUX - http://bit.ly/Sqc8aL
11/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Profitable Healthcare Stocks Forecasted To Grow EPS By At Least 25% http://bit.ly/UhMyaw $ALXN $ELN $FRX $VRTX @ZetaKap
10/4/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 High Growth Mid Cap Stocks Holding Down The Debt http://bit.ly/NYQlGY $AZPN $CX $FRX $GRPN $BBRY $SPLK $STM @ZetaKap
8/30/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

MagicDiligence
Weekly roundup of stocks moving in and out of Magic Formula Investing $TRW $FRX $MYGN and many others http://bit.ly/R9WJdy
8/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Mid Cap Stocks With Steady Profits And Projected EPS Growth Above 25% http://bit.ly/OQV8Wk $FRX $ANV $ACC $ELN $COG $SD @ZetaKap
8/11/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Healthcare Stocks Fueling Growth On Strong Profitability http://bit.ly/N8eV5c $PGNX $FRX $POZN $ELN @ZetaKap
7/3/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Mid Cap Healthcare Stocks Ready For Growth With Cash On Hand http://bit.ly/N839GJ $VVUS $SGEN $ALKS $QCOR $FRX $BMRN @ZetaKap
5/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Cockrell Group
$FRX Louise Chen at Auriga initiated coverage of Forest Laboratories with a Hold rating and $36 Price Target.
4/26/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Cockrell Group
$FRX Forest Labs Profit Falls http://bit.ly/J7yTb0
4/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

FRX Forest Laboratories, Inc.

FRX

Forest Laboratories, Inc.